Campath Linked to Autoimmune Diseases, Bleeding

October 14, 2013

Important Information

ClassAction.org is no longer reviewing claims for this case. The information here is for reference only. Up-to-date information and resources can be found here.

Comments |

At A Glance

This Alert Affects
Patients given Campath as part of their treatment for B-CLL, or off-label for Multiple Sclerosis
Damages
Idiopathic Thrombocytopenic Pupura (ITP), autoimmune disease leading to bleeding and bruising.
Company(ies)
Genzyme, Sanofi-Aventis.
Additional Details
Patients and authorities have been contacted by the manufacturer to advise about side effects and risks.
Date
FDA warning issued 2007